Ref: BSE/Parmax/26-27
Date: November 14, 2026

To,
The Department of Corporate Services,
BSE Limited, Mumbai
BSE Scrip Code: 540359
BSE Scrip ID: PARMAX

SUB: Statement of Utilization of issue proceeds raised through Issuance of Equity Shares and Warrants on Preferential Basis

Dear Sir / Madam,

Pursuant to Regulation 32(1) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations"), we hereby inform you that the Company has raised the funds through Issuance of Equity Shares and Warrants on Preferential Basis.

Further, statement confirming that there is no deviation or variation in the utilization of proceeds for the quarter ended September 30, 2026 is enclosed.

We request you to kindly take this information on record.

Thanking You

For Parmax Pharma Limited

UMANG ALKESH GOSALIA

Digitally signed by UMANG ALKESH GOSALIA
Date: 2026.11.14 21:34:49 +05'30'

.....

Umang Alkesh Gosalia
Managing Director
DIN: 05153830

Encl: As Above

Statement of Deviation/Variation in utilization of fund raised for the Quarter ended 30th September, 2026

Annexure – A

Name of listed entity	PARMAX PHARMA LIMITED
Mode of Fund Raising	PREFERENTIAL ISSUE
Date of Raising Funds	28-08-2026
Amount Raised	19,28,19,682*
Report filed for Quarter ended	30.09.2026
Monitoring Agency	NOT APPLICABLE
Monitoring Agency Name, if applicable	-
Is there a Deviation / Variation in use of funds raised	NO
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders	-
If Yes, Date of shareholder Approval	-
Explanation for the Deviation / Variation	-
Comments of the Audit Committee after review	-
Comments of the auditors, if any	-
Objects for which funds have been raised and where there has been a deviation, in the following table	-

Original Object	Modified Object, if any	Original Allocation (In Rs)	Modified allocation, if any	Funds Utilised	Amount of Deviation / Variation for the quarter according to applicable object	Remarks if any
Working Capital Requirement	N.A.	16,38,96,730	0	6,82,25,803	0	Proceeds utilised towards working capital
General Corporate Purposes	N.A.	2,89,22,952	0	22,64,305	0	Proceeds utilised towards Capital goods and Expenses

***Note:** An amount equivalent to Rs.1,95,74,449/- which represents 25% of the Issue Price was received at the time of subscription of Warrants as prescribed under SEBI (ICDR) Regulations. The balance subscription money of Rs. 5,87,23,344/- towards the Warrants Subscription will be received within 18 months from the date of Allotment upon exercise by the Warrants Holder.

Deviation or variation could mean:

(a) Deviation in the objects or purposes for which the funds have been raised or (b) Deviation in the amount of funds actually utilized as against what was originally disclosed or (c) Change in terms of a contract referred to in the fund-raising document i.e. prospectus, letter of offer, etc.